

Completion of Share Consolidation

Wellnex Life Limited (**ASX: WNX**) advises that the consolidation of share capital on a fifty (50) for one (1) basis as approved by shareholders at the Annual General Meeting held on 26 September 2024 is now complete.

The Company's post consolidation capital structure is as follows:

Class of Securities	ASX Code	Number
Fully Paid Ordinary Shares	WNX	28,038,750
Unlisted Options Exp 01/01/2026 @\$2.5	WNXAN	1,400,000
Unlisted Options Exp 06/02/2026 @\$7.5	WNXAB	146,316
Unlisted Options Exp 30/06/2025 @\$2.5	WNXAM	4,369,418
Unlisted Options Exp 20/07/2025 @\$5.0	WNXAK	550,000

In addition, the Company's current Convertible Note on issue had a conversion price of \$0.08 (refer to the Company's Notice of Annual General Meeting (Resolution 4) released to the ASX on 16 November 2023). This conversion price will be adjusted to \$4.0 post consolidation in accordance with the terms of the Convertible Note. No other changes to the terms of the Convertible Note.

New holding statements are being dispatched to shareholders on a post-consolidation basis.

Normal trading commences on **Friday, 18 October 2024** under ASX code '**WNX**'.

For more information, please refer to the Company's Notice of Annual General Meeting released to the ASX on 28 August 2024.

This announcement was approved by the Board of Directors.

-ENDS-

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX).

For further information, please contact:

Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/